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Abstract 
 
 Bacterial sortases have been widely studied for their usefulness in protein 
modification, however, the variable substrate specificity and activity between 
homologs of these enzymes is not yet fully characterized. To attempt to further 
understand sorting signal recognition, we have made advances towards a 
substrate bound structure of Streptococcus pneumoniae sortase A (SrtApneu). 
This enzyme displays a wide tolerance for alternate amino acids within the 
canonical LPXTG sorting motif. Our strategy involves a non-cleavable peptide 
analog that can be docked into the active site, allowing for elucidation of a 
structure displaying the key contacts that allow the enzyme to recognize alternate 
sorting signals. To this end, ketomethylene-linked isosteres were designed and 
synthesized, one of which was incorporated into a peptide via solid phase 
synthesis to produce a non-cleavable sorting signal for SrtApneu. Preliminary 
analysis of the substrate analog LPAG(keto)G for inhibition of SrtApneu activity in 
a model transpeptidation reaction suggested that this peptide was an effective 
inhibitor. Work towards understanding the activity of SrtApneu in relation to its 
oligomeric state was also undertaken, revealing a strong relationship between 
the extent of oligomerization and relative activity of SrtApneu, where extensive 
oligomerization resulted in minimally active samples. Purification of SrtApneu 
samples was optimized to produce pure monomeric samples of the enzyme, 
which showed improved transpeptidation activity. This work has helped lay the 
foundation for future efforts in producing a substrate-bound structure of SrtApneu.	
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1. Introduction 
1.1 Protein Engineering and Sortase A 
Protein engineering chemistry is a rapidly growing field of research, 
proven to be broadly applicable to problems in chemistry, molecular biology, and 
medicine. In many cases, protein engineering seeks to endow proteins with 
expanded functionality through a variety of permanent modification methods.1-5 
Among the numerous methods available for protein modification, 
chemoenzymatic systems have seen increasing use, aiding in the production of 
fluorescent-labeled proteins,6 antibody-drug conjugates,7 and bioconjugated 
nanoparticles,8 within a growing catalog of useful products. This method typically 
provides site-specific and rapid attachment of a desired modification, achieved 
through recognition and alteration of amino acids or sets of amino acids within a 
protein of interest.2, 9 Frequently, genetic modification is used to produce a 
recognition site for an enzyme with the ability to catalyze addition of a desired 
modification. The range of modifications is vast, however; most enzymes for 
protein modification function in exactly the same manner: a specific sequence of 
amino acids is recognized and a modification is made to or within the recognized 
site (Figure 1).  
In general, an individual enzyme catalyzes only a single reaction, meaning 
for each type of modification, a separate chemoenzymatic system exists. 
Formylglycine generating enzyme (FGE) recognizes a CXPXR amino acid 
sequence and modifies the cysteine residue to formylglycine co-translationally,10, 
	 2	
11 which can be used to generate oximes through reaction with hydroxyamines,11, 
12 a simple click reaction. Lipoic acid ligase attaches lipoic acid to lysine within its 
recognition sequence. This enzyme has been particularly useful in protein 
modification, as alteration of its substrates to include the azide and alkyne click 
handles has allowed for site specific incorporation of these selective and rapidly 
derivatized groups.13 This enzyme has also been employed in studies of protein-
protein interactions.14 Biotin ligase also modifies the lysine sidechain within its 
recognition sequence, attaching a biotin molecule to the ε-amine.15 Biotin often 
functions as a site specific tag for binding biomolecules to materials, examples of 
which include nanoparticles16 and quantum dots,17  as this small molecule 
selectively and tightly binds to proteins avidin and streptavidin.  
 
 
 
 
 
 
Figure 1. Generalized schematic of chemoenzymatic modification of proteins. A 
protein with an endogenous or inserted peptide recognition sequence (shown in 
black) is recognized by the protein modification enzyme. The modification is 
attached covalently within the recognition sequence. 
 
The sortase enzyme family has been well studied for use in protein 
modification. Sortases are transpeptidases found in Gram-positive bacteria18, 19, 
Enzyme recognition sequence 
Protein modification enzyme 
Modification to be added 
Chemoenzymatically modified protein 
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all of which maintain a nucleophilic cysteine within their active site that serves as 
the primary residue for catalysis.18, 20, 21 Sortases can be divided into multiple 
classes (A-F)21, 22, each exhibiting different structural and biochemical traits, 
some of which are shown in Table 1. Of most relevance to this study is the class 
A sortase (SrtA), which resides on the extracellular membrane of bacteria, 
embedded via a transmembrane domain18 that can be removed to produce 
soluble, recombinant SrtA for use in vitro. In vivo, SrtA typically performs a 
“housekeeping” function by anchoring multiple protein types to the extracellular 
wall.18, 19, 23-26 It has been determined that many proteins appended to the cell 
wall by SrtA are key virulence factors,27 including collagen adhesion proteins,28 
fibronectin binding proteins,29-31 and immunoglobulin binders32 that aide bacterial 
cell colonization and inhibit the host immune response. This in vivo function of 
SrtA makes it a viable drug target in Gram-positive bacteria, as several studies 
have shown that Gram-positive bacterial strains without SrtA exhibit reduced 
virulence.33-37 This makes it prudent to develop an in-depth understanding of 
sortase enzymology, as it may benefit the development of novel therapeutics to 
replace the rapidly failing catalog of current antibiotic drugs.38 While many 
advances have been made towards understanding specific homologs of SrtA, 
other less studied homologs may serve as excellent targets for further analysis 
as tools and drug targets.9, 29, 31, 39 
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Table 1. Sorting signals, substrates, and species specificity of all known sortase 
classes. [from Bradshaw et al.21] 
Sortase Class Motif Example 
Substrates 
Species 
A LPXTG Surface proteins40 All low GC content 
Gram-positive 
bacteria 
 
B NP(Q/K)TN Haem acquisition 
proteins41 
Low GC content 
Gram-positive 
bacilli and cocci 
 
C (I/L)(P/A)XTG Pillin subunits42, 43 Both low and high 
GC content Gram- 
positive bacteria 
 
D LPNTA Endospore 
envelope 
proteins44, 45 
 
Bacillus species 
E LAXTG Pili46 
 
High GC content 
Gram-positive 
bacteria 
 
F Unknown Unknown Actinobacteria 
 
 As each class of sortase performs a separate set of functions, each also 
recognizes its own sorting motif; typically a five amino acid sequence that is 
accepted into the enzyme active site for modification.21, 22 Specifically, SrtA 
homologs typically recognize an LPXTG motif,18, 19, 23, 24 where X is any amino 
acid. In proteins containing this motif, it is followed by a string of hydrophobic 
residues and a highly polar tail, dominated by arginine and lysine residues. This 
full segment (the sorting motif, hydrophobic, and hydrophilic residues) is referred 
to as a cell wall sorting signal (CWSS), as it indicates which proteins should be 
embedded in the cell membrane and targeted for binding, cleavage, and ligation 
	 5	
to the peptidoglycan of the extracellular wall.23, 47, 48 While sortases vary in terms 
of their sorting motif preferences, they are all believed to catalyze 
transpeptidation reactions similiar to that depicted in Figure 2 for sortase A from 
Staphylococcus aureus (SrtAstaph). In the case of SrtAstaph, the enzyme cleaves 
between the threonine and glycine residues in the sorting motif, forming an acyl-
enzyme intermediate that is resolved by an N-terminal amine nucleophile (in S. 
aureus, the lipid II pentaglycine moiety within the peptidoglycan).26 After 
transferring the substrate, the enzyme releases the newly fused protein, now 
appended to the cell wall.  
 
Figure 2. In vivo mechanism of transpeptidation by SrtAstaph.  
 
 
 
Sortase A 
Staphylococcus aureus 
+ 
NH2 
NH2 
L 
P 
X 
T 
G 
+ 
NH2 
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NH2 
S
O
H2N-GGGGG 
protein 
Lipid II 
(peptidoglycan 
precursor) 
L 
P 
X 
T 
(G) 
 
5 
Lipid II -       
anchored protein 
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The innate ability of sortases to catalyze site-specific ligations has been 
used extensively in protein engineering chemistry to produce a large catalog of 
proteins and peptides conjugated to fluorophores,49 nanoparticles,8 lipid 
nanodiscs,50 other proteins,51 and even live cells52, 53 (Figure 3). The protein or 
peptide ligation partners can function as either the amine nucleophile or 
substrate (sorting signal) in the transpeptidation reaction, which further enhances 
the versatility of this approach.51, 54-56 This has been used to modify the C- and N-
termini of proteins, in addition to surface loops.51, 56 Several homologs of sortase 
have been used in protein modification efforts. While most studies are carried out 
with SrtAstaph, several modifications have been demonstrated with the SrtA 
homolog from Streptococcus pyogenes9, 49, 57 (SrtApyogenes) and, more recently, 
with the evolved mutants of SrtAstaph, which demonstrate higher reaction rates,58 
altered substrate profiles,58-60 and Ca2+ independence.61, 62 
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Figure 3. Protein modification using in vitro transpeptidation catalyzed by SrtA. 
This strategy can be applied to a variety of ligation partners, shown in the bottom 
half of the figure, facilitating the construction of diverse protein fusions. 
 
1.2 Expanded Substrate Tolerance of Sortase Homologs 
In addition to increases in the diversity of protein engineering applications 
that employ sortases, there have also been a number of studies focused on 
circumventing critical limitations of the method itself. With respect to SrtAstaph, 
slow reaction rates, reversibility, strict substrate specificity,63 and limited 
acceptance of structurally diverse amine nucleophiles63-65 reduce the usefulness 
of the enzyme for certain applications. Slow reaction rates can often be 
overcome by altering reaction conditions and reversibility can be diminished by 
site-specific 
ligation 
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LPXTG H2N-(G)n proteins/synthetic peptides  
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SH
sortase A 
S
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H2N-G-XX 
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acyl enzyme 
intermediate 
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H2N-(G)n- Label 
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the use of specially designed substrates.66, 67 Our lab has previously developed 
substrates containing the Ni2+ binding motif GGHG on the C-terminus, which, 
upon cleavage, demonstrated a reduced capacity to function as a nucleophile in 
the reverse reaction to reform the substrate.66 Depsipeptides have also been 
used effectively modify the N-terminus of proteins, as processing substrates with 
an ester linkeage produces C-terminal fragments with no available amine, 
eliminating the possibility the reverse reaction to regenerate the starting 
material.67 In contrast to the issue of reversibility, substrate specificity and limits 
of accepted nucleophiles cannot be overcome by modifying the materials or 
conditions used in the reaction, as they are founded in enzyme structure and the 
mechanism of catalysis. In response, multiple groups have now generated 
evolved SrtA mutants with improved catalytic activity, modified substrate 
tolerance, and independence from certain reaction cofactors.48-52 While useful, 
these strategies often rely on laborious directed evolution strategies in order to 
identify useful mutations. As a complement to these approaches, our group has 
been exploring the reactivity of naturally occurring sortase homologs as a way to 
further expand the scope and versatility of sortase-mediated protein engineering.  
With respect to substrate specificity, bioinformatics studies suggest that 
the vast majority of SrtA homologs are specific for LPXTG motifs68. Using the 
CW-PRED2 algorithm, sortase substrates have been predicted from more than 
177 bacterial genomes.61 SrtAstaph was predicted to have between 15 and 21 
substrates across 13 strains, all of which demonstrated a high preference for 
	 9	
leucine in position 1, proline in position 2, threonine in position 4, and glycine in 
position 5. Position 6 was also analyzed and demonstrated no preference for this 
position in sortase substrates. Position 3, the variable position in the sorting 
motif, was frequently occupied by a charged residue; however, no strong 
preference for specific amino acids was determined for this position. 
Interestingly, substrate prediction demonstrated that in about 10% of substrates, 
the 4th position was occupied by alanine. In vitro analysis of these preferences 
with discrete peptide substrates shows there are some discrepancies between 
the actual and predicted sorting sequences of some sortase homologs. 
Specifically, it has been demonstrated that SrtAstaph has a preference for glycine 
in the 6th position, outside of the canonical LPXTG sorting motif.69 Further, 
studies by Kruger et al. have demonstrated that SrtAstaph accepts several amino 
acids in the 4th position of the sorting motif, a trait not predicted by bioinformatics 
algorithms.69 Building from these initial studies, our group has now shown that 
SrtA homologs can exhibit substantial differences in tolerance for amino acids in 
multiple positions of the sorting sequence. The most substantial deviations from 
the canonical LPXTG sorting motif were found in the 4th and 5th positions of the 
amino acid sorting sequence. An example for the 5th position tolerance is shown 
in Table 2. These data revealed that many SrtA homologs accept several amino 
acids in the 5th position of the sorting sequence. A particularly wide tolerance to 
substrates with non-canonical amino acids in the 5th position can be seen in 
Streptococcus pneumoniae SrtA (SrtApneu).  
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Figure 4. Amino acid preferences of selected SrtA homologs for the 5th position 
of the SrtA recognition sequence LPXTG [Nikghalb, Antos unpublished data]. 
 
In addition to the expanded substrate tolerance, the reaction completion 
percentages determined by HPLC and MS analysis of these model sortase-
catalyzed ligation reactions demonstrate that SrtApneu prefers the substrate 
LPATA in vitro, instead of the canonical LPXTG substrate. This is in clear 
contrast to SrtAstaph, which prefers only LPATG containing substrates. While 
some conversions are sub-optimal for use in protein engineering applications, the 
tolerance data shown in Figure 4 above is the result of unoptimized reactions, 
and even low percent conversions may be improved by modifying the reaction 
conditions. Importantly, this would provide a route for expanding the scope of the 
sortase-mediated protein engineering, potentially increasing the range of 
endogenous protein targets that are compatible with sortase without the need to 
insertion of a recognition sequence in the primary structure, ultimately saving 
V Y S W L Nle G A N F Q C 
S. aureus 3 1 1 0 0 0 86 2 0 1 2 5 
S. suis 2 2 67 0 0 2 71 74 58 3 3 73 
S. oralis 2 1 54 0 0 1 74 46 3 2 6 48 
S. pneumoniae 39 14 84 11 41 14 81 92 48 29 11 76 
L. monocytogenes 4 43 41 6 1 2 86 15 22 30 1 42 
E. faecalis 1 0 7 0 0 1 7 5 6 3 1 10 
L. lactis 5 1 44 0 1 1 83 66 28 2 1 32 
B. anthracis 1 2 8 0 0 1 42 22 17 1 0 17 
L. plantarum 1 1 2 0 3 0 18 3 2 1 1 8 
sortase A 
Abz-LPATZG-K(Dnp)  Abz-LPAT-NHOH + ZG-K(Dnp) 
H2N-OH 
excess 
Z   = 
Sortase A 
homolog 
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time and resources. 
Regarding the homolog SrtApneu, its particularly broad substrate tolerance 
presents an interesting issue to be examined with respect to the mechanism of 
substrate recognition. It is known that SrtAstaph undergoes structural 
rearrangement upon correct substrate binding, which facilitates catalysis of 
transpeptidation.70, 71 The wide substrate tolerance described above for SrtApneu 
suggests that it may harbor a unique mode of substrate recognition. A thorough 
understanding this substrate recognition at the molecular level would benefit not 
only the continued development of SrtApneu for use in protein engineering, but 
would also contribute to our fundamental understanding of sortase enzymology. 
Unfortunately, no structure of SrtApneu has been published to date, which 
precludes a more in depth analysis of its substrate recognition and catalytic 
mechanism.  
 
1.3 Substrate Binding and Structure of SrtA Homologs 
Published solution NMR structures have been determined for SrtAstaph71 
and sortase A from Bacillus anthracis (SrtAanth)72 with a bound substrate analog, 
referred to as LPAT*, which utilizes a disulfide bond forming linker on the C-
terminus that irreversibly binds to the enzyme active site.71 These structures 
have been instrumental in developing an understanding of the reverse 
protonation mechanism of catalysis73 and the enzyme-substrate interactions of 
the first four amino acids within the sorting sequence.  
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Figure 5. (A) Solution NMR structure of SrtAstaph. Arginine (blue), cysteine 
(yellow), and histidine (green) stick structures represent the key catalytic 
residues. (B) Predicted structure of SrtApneu from the Phyre 2 structural prediction 
server74. (C) Active site architecture of the solution NMR structure of SrtAstaph 
with the bound substrate analog LPAT* (PDB ID: 2KID). Side chains of residues 
surrounding the active are shown as stick structures, highlighting the number of 
hydrophobic interactions stabilizing the substrate-bound state.  
  
B 
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 In terms of overall structure, sortases include an 8-stranded beta barrel 
fold considered to be unique to this family of enzymes.20 This β barrel is 
surrounded by combinations of α and 310 helices and loops that vary in size and 
conformation between classes and homologs.21, 23, 72, 75-77 In general, SrtA 
homologs contain three catalytic residues: cysteine, arginine, and histidine, within 
the active site.78, 79 In SrtAstaph, the active site floor, or binding groove, is formed 
from strands β4 and β7 (Figures 5 and 6). The walls of this binding pocket are 
composed of loops joining other β strands and α helices in the structure. Within 
the active site, bound substrates are found in an “L” shape, facilitated by the 
proline residue, which angles the scissile bond towards the active site cysteine. 
The leucine sidechain makes hydrophobic contacts with residues in the β6/β7 
loops and proline is buried in a hydrophobic groove formed by residues of the β4 
and β7 strands. The alanine residue displays a hydrophobic interaction with the 
H1 helix, however, it is important to note that space exists for projection of larger 
sidechains away from the enzyme, partially explaining the low specificity for 
amino acids in this position. The threonine in the 4th position of the amino acid 
sorting motif functions forces the sidechain of a tryptophan residue up and away 
from the active site, moving the catalytic cysteine residue towards the scissile 
peptide bond.71 This is considered to be one of the most important interactions in 
substrate recognition, as substrates with glycine at this position are completely 
inactive63. 
 Binding of the sorting motif in the active site induces further 
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conformational changes in some homologs of SrtA. In SrtAstaph, loop β6/β7 
undergoes a large disordered to ordered transition which is key to substrate 
binding, as the recognition of the sorting sequence leucine residue relies on 
multiple interactions in this strand.71, 80-82 The nucleophilic attack of the scissile 
peptide bond by the active site cysteine shifts the β7/β8 loop to reveal the 
backside of the active site to incoming nucleophiles.71 This also facilitates 
recognition of the threonine residue, as mentioned above. The size of the β7/β8 
loop is predicted to be important for recognition of the 5th position in the amino 
acid sorting sequence (Nikghalb and Antos, unpublished data). SrtAstaph displays 
a particularly large loop extending from the β7/β8 strands (Figure 5), which may 
account for the high selectivity for glycine in the 5th position of the sorting 
sequence.  
Apart from SrtAstaph, NMR data for SrtAanth bound to the LPAT* substrate 
analog72 shows a number of similar features, including the cys-his-arg catalytic 
triad and the structure of the substrate binding groove. The binding pocket in this 
enzyme appears to be mostly preformed, however, in contrast to that of 
SrtAstaph.72 Other notable differences between these structures exist, particularly 
the direction of the threonine residue, which points down towards the guanidino 
group of arginine. This supports the presence of an oxyanion hole to stabilize the 
tetrahedral transition state in the catalytic cycle, as initially hypothesized from the 
structure of SrtBanth.83 Additionally, the β7/β8 loop of this homolog demonstrates 
a similar structural transition upon substrate binding to that of SrtAstaph  β6/β7 
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loop, whereas the β6/β7 loop of is ordered in both the apo and substrate-bound 
forms of the enzyme. An interesting N-terminal appendage, similar to that seen in 
the SrtC subclass,84 is thought to protect the active site from hydrolysis of the 
substrate, facilitating reactivity with the intended N-containing nucleophile72. 
While a structure of SrtApneu bound to a substrate analog has not been 
reported, structure prediction tools reveal features that may play a role in the 
expanded substrate tolerance of this enzyme. One-to-one threading by the 
Phyre274 structural prediction server has allowed for prediction of the structure of 
SrtApneu (Figure 5). SrtApneu is predicted to have a smaller β7/β8 loop than that of 
SrtAstaph, which could account for its increased substrate promiscuity, as this 
region should be involved in recognition of amino acids in the 4th and 5th position 
of the sorting sequence. 
Another variable aspect of SrtA structure and substrate recognition can be 
seen in metal ion sensitivity. Many sortases20, 85-87 are Ca2+ dependent, where the 
bound ion improves the catalytic activity of the enzyme. SrtAstaph binds calcium 
with a set of acidic residues in the β6/β7 loop, stabilizing the substrate bound 
conformation70, 71, 80. The presence of Ca2+ ion in reactions with this homolog 
significantly increases the reaction rate20. Again, in contrast to SrtAstaph, sortases 
have also been discovered which are independent of Ca2+ ion88, 89. A recently 
determined example of this is Streptococcus suis SrtA (SrtAsuis), where Ca2+ ion 
has no effect on reaction rate or total conversion. Our lab has previously 
determined that Ca2+ ion has little to no effect on the reaction rates of SrtApneu, 
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which indicates it may recognize and bind substrates in a mechanism 
fundamentally different than SrtAstaph.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6. (A) Surface structure representation of SrtAstaph with the bound 
substrate analog LPAT* (green). (B) Mechanism of transpeptidation within the 
active site of SrtA. The red box denotes the acyl-enzyme intermediate that 
closely resembles the structural state of the structure at left. 
 
Unfortunately, these structures lack a complete description of substrate 
binding and recognition, as they do not illustrate interactions between the fifth 
position of the sorting sequence and the enzyme. The substrate analog used to 
collect the data from the studies by Suree et al.71 and Chan et al.72 closely 
mimics the acyl-enzyme intermediate, designated in Figure 6 by the red box, 
which involves only the first four amino acids (LPAT) in the sorting motif. That 
said, additional work by Suree and coworkers has revealed some regions of 
SrtAstaph implicated in recognition of the nucleophile and fifth amino acid 
positions71 (Figure 7). 15N-HSQC monitored titration of triglycine resulted in three 
regions displaying perturbed backbone resonances, presumably from the binding 
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of triglycine to these regions. These amino acids primarily lie around the sites 
where the 5th position amino acid should contact the binding pocket. Interestingly, 
sequence alignment of various SrtA homologs displays a marked difference in 
primary structure in these regions (Figure 7). This correlates with data from our 
lab (Figure 4) demonstrating the greatest differences from canonical LPXTG 
sorting motif recognition occur in the fifth amino acid, and highlights the need for 
a more rigorous assessment of contacts between the 5th position amino acid and 
SrtA during substrate recognition.  
Figure 7. (A) Sequence alignment of selected SrtA homologs90, 91. The regions of 
greatest difference (boxed) correspond to the regions highlighted in the structure 
(B), indicating the least sequence homology lies on the structural features 
predicted to interact with the 5th position of the sorting sequence. (B) Surface 
representation of SrtAstaph bound to substrate analog LPAT* (PDB ID: 2KID). 
Residues highlighted in magenta were determined to interact with the incoming 
nucleophile by analysis of peak perturbation during a 15N-HSQC monitored 
titration of SrtAstaph with G3. These residues primarily lie around the region of the 
binding pocket predicted to interact with the C-terminus of the sorting signal.71  
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Region 3 
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1.4 Enzyme Activity as a Function of Oligomeric State and Active Site 
Modifications 
 
Previous studies have demonstrated the presence of both dimeric and 
monomeric forms of SrtA both in vivo and in vitro.87, 92-94 In vitro, SrtAstaph samples 
were subjected to several modes of analysis to confirm the presence of 
oligomers (Figure 8) and assess the strength of the dimer association. 
Specifically, analytical sedimentation equilibrium ultracentrifugation calculated an 
average Kd for the monomer-dimer equilibrium to be 54.6 ± 6.9 µM, considered a 
moderate interaction between the subunits of the complex.92 In vitro, SrtAstaph 
catalytic activity has been evaluated for both the monomeric and dimeric forms of 
the enzyme, where ligation reactions performed with monomeric preparations did 
not function as well as those with high concentrations of the homodimer.92 The 
dimer was predicted to be as much as 8 times as active as the monomer based 
on steady state analysis of reactions at various concentrations (Figure 9).  
 
 
 
 
 
 
Figure 8. In each panel, lane 1 is Coomassie staining and Lane 2 is Western 
Blotting with anti-His6x antibody. (A) SDS-PAGE analysis of truncated SrtAstaph. 
(B) SDS-PAGE analysis of wild-type SrtAstaph. (C) Native PAGE analysis of 
truncated SrtAstaph. (Adapted with permission from Lu et al.92 Copyright 2007 
American Chemical Society) 
	 19	
 
 
 
 
 
 
 
 
Figure 9. Steady state reaction velocity analysis with varying [LPETG] for (A) 
monomer and (B) dimeric SrtAstaph. (Adapted with permission from Lu et al.92 
Copyright 2007 American Chemical Society) 
 
 In vivo, Zhu et al. demonstrated that higher levels of monomeric SrtA 
increase the amount of sortase-catalyzed surface attached protein by inserting a 
non-dimerizing mutant of SrtA into a knockout strain of S. aureus.93, 94 This 
indicated greater catalytic activity for the monomeric form, in clear contrast to the 
in vitro studies. Further, the increased presence of surface attached proteins 
rendered bacteria with fully monomeric sortase more invasive than the wild-type 
strain. The dimerization observed in this homolog is anticipated to be biologically 
relevant as a mechanism for deactivating the enzyme when rapid attachment of 
proteins to the cell wall is not necessary.92, 94 Dimerization has been observed as 
a mechanism of regulation in other enzymes.95 Analysis of this monomer-dimer 
interplay has not been performed in other homologs of SrtA, however, based on 
the data above it is an essential piece of regulation which is not yet understood.  
Regarding the modes of oligomerization available to SrtAstaph, it is not 
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certain how this enzyme associates in vivo or in vitro, as no structure has been 
published to demonstrate this phenomenon. The crystal structure of SrtAstaph96 
helped guide Zhu et al. in developing a set of mutants with diminished 
dimerization capacity.  SrtAstaph with any one of the mutations Y143A, K137A, or 
N137A demonstrated greater than 93% lower dimerization than the original 
truncated SrtAstaph. From these data, the authors hypothesized the Y143 and 
K137 mutations may disrupt a cation-π interaction which initiates dimerization. 
Cation-π interactions are seen in other proteins to facilitate dimerization and are 
often stabilized by additional charge interactions,97-99 which is believed to be why 
mutation of N137 also diminishes the presence of the sortase dimer. These 
contacts would facilitate structural rearrangement to create further hydrophobic 
and hydrogen bonding, generating stable homodimers.93  
Further information relevant to the work described here comes from a 
structure of SrtApneu (PDB ID: 4O8L) deposited in the Protein Data Bank but not 
yet published in a written article. This x-ray crystallography structure shows a 
domain swapped dimer, where a large portion of the anticipated active site 
associates with the complimentary enzyme (Figure 10). More specifically, 
strands β7 and β8 and loops β6/β7 and β7/β8 are rotated out of the enzyme core 
structure to form contacts with the opposite monomer in the domain swapped 
dimer. Enzymes in this state would most likely be inactivated, as the catalytic 
cysteine residue lies on β7 loop, and is therefore buried in the domain swapped 
form. While it is not known if this structure is an artifact of enzyme preparation or 
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an authentic representation of the enzyme in vitro, it does demonstrate the ability 
of SrtApneu to form stable, potentially inactivated, dimer constructs. 
 
Figure 10. (A) The domain swapped dimer of SrtApneu (PDB ID: 4O8L) (B) A 
domain swapped monomer from the structure of SrtApneu in (A). (C) Predicted 
structure of SrtApneu from the Phyre274 structural prediction server. In both 
structures, the green colored areas pertain to the domain swapped portion of the 
structure shown in (A).  
 
An additional factor that may contribute to sortase activity comes from the 
crystal structure of SrtApyogenes, where a stable sulfenic acid modification was 
discovered in the active site of a crystal structure.75 The sulfenic acid modification 
discovered was anticipated to be of a non-active form of the enzyme, as the 
active site cysteine would no longer be available to function as the primary 
nucleophile in catalysis. Interestingly, the modified cysteine stimulated 
conformational change in the enzyme similar to what is anticipated to occur with 
A B 
C β7/β8 loop 
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a bound substrate, suggesting that structural rearrangement is an essential 
aspect to the mechanism of transpeptidation in SrtApyogenes.75 The authors 
predicted that this could be biologically relevant as a potential method of 
inactivation by host immune systems releasing reactive oxygen species. 
McCafferty et al. determined that the reverse protonation mechanism of SrtAstaph 
confers protection from oxidation onto the active site cysteine, as the high pKa of 
this residue side chain resists oxidation.100 More recently, use of reactive Cu 
chelating peptides has demonstrated the potential for the active site cysteine of 
SrtAstaph to be oxidized to sulfenic acid, which the researchers in this study 
suggested would function as a form of irreversible activation101.  
 
1.5 Project Goals and Overview  
 Given the importance of sortases as tools for protein engineering and as 
targets for therapeutic development, it is critical to establish a detailed 
understanding of substrate recognition among homologs with diverse substrate 
tolerances. To this end, the long-term goal of this project is to determine the 
structure of the promiscuous enzyme SrtApneu covalently docked with substrate 
analog. As described in this thesis, our approach involves the construction of 
ketomethylene-based sorting signal analogs, which we anticipate to be non-
cleavable by the sortase enzyme (Figure 11). Importantly, the use of 
ketomethylene dipeptide isosteres will mimic amino acids in the 4th and 5th 
position of the sortase substrate motif, allowing for elucidation of key interactions 
between the enzyme and these residues. In addition, we believe this can provide 
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a more complete picture of substrate recognition in SrtA, and more specifically, 
the homolog from S. pneumoniae, as there is currently no published data 
regarding this enzyme’s structure. Here we describe progress toward 
synthesizing the requisite ketomethylene building blocks, as well as preliminary 
evidence indicating that these substrate analogs are able to interact with the 
enzyme active site. We also describe an unanticipated oligomerization of 
recombinant SrtApneu, and the development of methods for refolding, purifying, 
reproducibly generating preparations of SrtApneu with consistent activity. These 
studies provide an important foundation both for utilizing SrtApneu as a tool for 
protein engineering, and for further structural characterization of this enzyme. 
 
 
Figure 11. Anticipated mechanism of trapping for the proposed ketomethylene 
substrate analogs. 
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2. Preparation and Characterization of Recombinant 
Streptococcus pneumoniae sortase A (SrtApneu) 
 
2.1 Expression, Refolding and Purification of SrtApneu 
 Initial work on this project was aimed at producing a stock of SrtApneu to be 
used for structural characterization. To this end, an expression vector for SrtApneu 
was obtained via commercial gene synthesis from DNA 2.0, which encoded a 
truncated version of SrtApneu fused to an N-terminal His6 tag. In this construct, the 
first 80 amino acids, corresponding to the hydrophobic transmembrane region, 
were removed to increase solubility in aqueous buffers. Initially, SrtApneu was 
expressed from E. coli BL21(DE3) using standard molecular biology techniques. 
After cell lysis, the enzyme was isolated from the soluble fraction using 
immobilized metal affinity chromatography (IMAC).  Prior work in the laboratory 
had succeeded in producing an active preparation of this enzyme, hereafter 
referred to as batch 1. An additional enzyme stock was generated for this work 
(batch 2) using a batch purification protocol for initial binding of enzyme to nickel 
nitriloacetic acid (Ni- NTA) resin. The eluted material from the first round of 
purification was re-purified through standard gravity-flow IMAC protocols to 
improve the purity of these samples. The sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis of batch 2 (Figure 12) showed an 
intense band near 26 kDa, in reasonable agreement with the calculated 
molecular weight of 20.1 kDa for SrtApneu This gel also demonstrated the good 
purity and high concentration of the collected samples. We also observed what 
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appeared to be SrtApneu dimer at ~50 kDa that persisted in the sample despite the 
reducing and denaturing conditions of the SDS-PAGE loading buffer. 
  
 
 
  
 
 
 
   
 
 
  
 
Figure 12. SDS-PAGE gel showing samples from the expression and purification 
of batch 2 SrtApneu  prepared from IMAC purification using Ni-NTA resin. 
  
 Model sortase-mediated ligation (SML) reactions using a known peptide 
substrate (Abz-LPATA-GK(Dnp)) and the strong nucleophile H2NOH were used 
to assess the in vitro reactivity of batch 2 (Figure 13). After a 24 hour incubation 
at room temperature, the reactions were analyzed by reverse phase high 
performance liquid chromatography (RP-HPLC). Surprisingly, the batch 2 
enzyme stocks produced only minimal product formation (4.8% reaction 
conversion) when compared to the batch 1 positive control (95% conversion).  
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Figure 13. RP-HPLC analysis of model SML reactions demonstrating the 
difference in activity between batches 1 and 2 of SrtApneu. Reactions were 
analyzed after 24 hrs of incubation at room temperature. 40 µM Abz-LPATA-
GK(Dnp) was used in this reaction. 
 
As a result of the low observed reactivity for batch 2, a new batch of 
SrtApneu  (batch 3) was expressed and purified by standard IMAC protocols from 
newly transformed E. coli to eliminate the possibility of issues with the previous 
cell line (Figure 14). As expected, an intense band was seen around 26 kDa, 
matching closely to the expected molecular mass of SrtApneu from SDS-PAGE 
analysis. We further analyzed these samples through mass spectrometry. 
Reconstruction of the enzyme molecular mass from the observed charge ladder 
(Figure 15) returned an uncharged mass of 20145 Da (expected MW = 20145 
Da). Model SML reactions prepared from the batch 3 SrtApneu also demonstrated 
low reactivity (Figure 16), where only 21% conversion of the peptide substrate 
was observed. 
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Figure 14. SDS-PAGE gel representative of SrtApneu batch 3  samples prepared 
from IMAC purification using Ni-NTA resin. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 15. (A) ESI-MS spectrum of batch 3 SrtApneu (B) Deconvoluted mass 
spectrum of SrtApneu batch 3. The primary mass shown here, 20145 Da, is 
identical to that predicted for this SrtApneu truncation. 
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Figure 16. RP-HPLC analysis of model SML reactions demonstrating the 
difference in activity between batches 1 and 3 of SrtApneu. Reactions were 
analyzed after 24 hrs of incubation at room temperature.  
 
 To further investigate the observed discrepancy in enzyme reactivity, we 
analyzed our catalog of SrtApneu samples by native PAGE (Figure 17). In 
contrast to reducing SDS-PAGE, which suggested that all enzyme stocks were 
monomeric and identical, native PAGE revealed some striking differences. In 
particular, native PAGE revealed a number of higher molecular weight bands in 
all samples of SrtApneu. Based on the absence of these prominent bands under 
denaturing conditions, we hypothesized that they represented oligomers of the 
enzyme, a phenomenon known to occur in other sortase homologs.87, 92, 94 
0 5 10 
Abz-LPATAG-K(Dnp)  
A
bs
or
ba
nc
e 
(3
30
 n
m
) 
Elution time (min) 
AG-K(Dnp) 
RP-HPLC 
 
SrtApneu Abz-LPATAG-K(Dnp)  Abz-LPAT-NHOH + AG-K(Dnp) 
H2N-OH 
excess 
Abz-LPATAG-K(Dnp)  
A
bs
or
ba
nc
e 
(3
30
 n
m
) 
Elution time (min) 
 AG-K(Dnp) 
RP-HPLC 
0 5 10 
Batch 3 SrtApneu 
Batch 1 SrtApneu 
21% conversion 
~95% conversion 
	 29	
Interestingly, batch 1 SrtApneu, which exhibited good in vitro reactivity and was 
used as a positive control in model SML reactions, showed a stark difference in 
the oligomer/monomer ratio when compared to newly prepared samples (batch 2 
and batch 3).  Specifically, batch 1 in lane 1 contained a lower concentration of 
oligomerized sortase bands, particularly in the area that we propose corresponds 
to trimeric and tetrameric SrtApneu, in addition to a higher concentration of 
monomer than batch 2 and 3 samples in lanes 2 and 3, respectively. While both 
batch 2 and batch 3 samples demonstrated oligomerization in this analysis, we 
elected to continue our analysis with the batch 3 SrtApneu samples, as these had 
been developed using identical IMAC purification procedures used in the lab. 
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Figure 17. Native PAGE gel demonstrating the presence of potential oligomeric 
states in stocks of SrtApneu. Samples were loaded in equimolar amounts. The 
predicted subunit count is given at right for each boxed region. Of particular 
interest here are lanes 1 and 3, which demonstrate variation in the band patterns 
between batch 1 and batch 3 SrtApneu. Specifically, batch 1 shows a smaller 
amount of higher molecular mass bands than batch 3, and a greater 
concentration of protein anticipated to be the SrtApneu monomer. Lane 2 came 
from the batch 2 SrtApneu expression and also displays the oligomerized band 
pattern, which differs from that of batch 1. 
 
The presence of SrtApneu in solution was further confirmed by size 
exclusion fast protein liquid chromatography (SE-FPLC), which was able to 
resolve samples of SrtApneu into its assembled components (Figure 18). 
Resolution of different molecular weight species was clearly seen in FPLC 
traces, and native PAGE analysis of fractions from SE-FPLC separation showed 
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the same band pattern as unprocessed samples of the enzyme (Figure 19). 
Based on these data, it was concluded that SrtApneu exists as about 93% 
oligomer in batch 3, which we reasoned was interfering with the enzymatic 
activity of the new preparation. In addition, given that the most active prep of 
SrtApneu (batch 1) appeared to have the highest monomer content (Figures 16 
and 17), we hypothesized that the monomer was the active form of the enzyme.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 18. SE-FPLC trace demonstrating the presence of multiple oligomeric 
species in a pure sample of batch 3 SrtApneu. This sample was separated at a 
0.75 mL/min flowrate. 
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Figure 19. Native PAGE of the SE-FPLC fractions 8-11 from the separation in 
Figure 18. Similar band patterns can be seen in the fractions as in a sample of 
the injected batch 3 SrtApneu in lane 1. 
 
To begin to explore this phenomenon and understand how to generate 
fully active, monomeric SrtApneu preparations, samples were subjected to 
conditions that potentiated disassembly of the enzyme oligomers. First attempts 
at this involved incubation of serial diluted samples of the batch 3 stock at room 
temperature to evaluate the possibility of high stock concentrations forcing the 
monomer-oligomer equilibrium towards the oligomerized state. Unfortunately, the 
presence of high molecular weight bands seen in native PAGE analysis of these 
diluted samples was unchanged (Figure 20). Notably, this observation did not 
align with previous accounts of sortase dimerization, as the dissociation constant 
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determined for SrtAstaph dimer/monomer equilibrium (55 µM) suggested that the 
low affinity interactions between monomers would favor dissociation at low 
concentrations92. This indicated that SrtApneu oligomerization could be 
fundamentally different from that found in SrtAstaph.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Native PAGE gel of room temperature incubated serial dilutions of 
batch 3 SrtApneu.  
 
Fortunately, further attempts at disassembling SrtApneu were more 
successful. We next reasoned that oligomerization could be dependent on 
temperature. To evaluate this, samples of batch 3 SrtApneu were incubated at 37 
oC and room temperature for 24 hours at 50 µM, 100 µM, and 300 µM 
concentrations. The relative disassembly of the putative oligomers was analyzed 
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via native PAGE. It was immediately apparent from native PAGE that incubation 
at 37 oC for 24 hrs degraded the oligomers into monomeric enzyme, generating a 
band pattern that was similar to the active batch 1 preparation (Figure 21). In 
contrast, room temperature incubation yielded material that was identical to the 
original batch 3 stock. Lower incubation concentrations also appeared to slightly 
improve the monomer content, although this did not appear to be as substantial. 
SE-FPLC analysis of undiluted samples of batch 3 SrtApneu heated for more than 
24 hours also demonstrated an increase in peak area where the monomer was 
expected, mirroring the results of native PAGE experiments for shorter incubation 
times (Figure 22). Use of  “heat-disassembled” batch 3 samples in a model SML 
reaction resulted in greater product formation. In particular, enzyme samples 
incubated at 37 °C for 1 week (Figure 23) produced conversion percentages of 
95% after 48 hours, very near the batch 1 positive control reactions, which 
exhibited 97% conversion in the same period of time (Figure 24). Reactions 
using batch 3 SrtApneu produced only 35% conversion in this reaction set. This 
indicated that the oligomerized states of the enzyme most likely exhibit some 
control over the rate and effectiveness of SML.		While incubation of batch 3 
samples for extended periods of time (>24 hrs) resulted in somewhat greater 
dissociation of high molecular weight bands (Figure 23), aggregation was also 
observed in SE-FPLC traces of samples incubated for these extended periods of 
time  (Figure 22). 	
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Figure 21. Native PAGE gel demonstrating the effect of heating samples of 
SrtApneu. Lanes 1 and 3 contain diluted samples of batch 3 enzyme heated for 24 
hrs at 37 °C. The band patterns of the heated samples more closely resemble 
that of the batch 1 samples in lane 6 than the batch 3 stock in lane 5.  
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Figure 22. SE-FPLC traces showing the oligomer distribution in samples of 
SrtApneu heated for (A) 3 days and (B) 7 days at 37 °C. A peak centered around 
7.5 mL developed after longer periods of heating, anticipated to be aggregation 
of the enzyme.  
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Figure 23. Native PAGE gel demonstrating the effects of 7 days of incubation at 
37 °C on diluted samples of batch 3 SrtApneu with and without 10 mM 
dithiothreitol (DTT). As in Figure 21, the band pattern of the heat-treated batch 3 
samples looks more similar to the batch 1 SrtApneu than untreated batch 3 
SrtApneu.  
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Figure 24. RP-HPLC analysis of reactions assembled with preparations of 
SrtApneu from the gel in Figure 23. Reactions were incubated at room 
temperature for 48 hrs. The enzyme preparation used in the reaction is denoted 
by the lane number at the right of the trace. Heated samples of batch 3 SrtApneu 
produced similar conversion to the batch 1 stock reactions, which matches the 
gel showing similar band patterns between the three samples. 
  
 Having succeeded in recovering some enzyme activity by heat treatment, 
we next evaluated the behavior of heat-disassembled SrtApneu after prolonged 
incubation at room temperature, 4 oC, or -80 oC, (Figure 25). None of these 
treatments resulted in reversion of the native PAGE band pattern back to the 
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initial assembled state, and the desired monomeric SrtApneu remained present. 
Overall, this indicated the SrtApneu assembly process potentially involves an  
equilibrium that favors the monomeric form of the enzyme. As mentioned 
previously, however, dilution of the batch 3 stocks without heating did not appear 
to diminish the presence of high molecular weight bands. Along with the 
information collected from the heating experiments, this suggested the presence 
of an activation barrier for converting between the monomeric and oligomeric 
forms of the enzyme, which can be overcome by heating the samples.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Native PAGE gel showing batch 3 SrtApneu heat-disassembled for 24 
hours at variable concentrations and incubated for 24 hours at room temperature, 
4 °C, and -80 °C. All samples were loaded in equimolar amounts. 
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 To apply the information gained from the heating experiments to 
production of active SrtApneu samples, alternative expression temperatures were 
tested to determine if production of the protein at lower temperatures would 
minimize the oligomer concentrations. After expressions attempts at 16, 25, and 
37 oC, analysis by SE-FPLC determined there was no appreciable difference in 
the oligomer content following IMAC purification (Figure 26), as high relative 
oligomer concentrations could be seen in each injected sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. SE-FPLC traces demonstrating relative monomer concentration in 
samples of SrtApneu expressed at variable temperatures and purified by standard 
IMAC protocols. (A) Expression at 37 °C, (B) expression at 25 °C, and (C) 
expression at 16 °C did not appear to alter the relative concentration of 
monomeric SrtApneu by this analysis. 
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 Based on the information gathered from the experiments described above, 
we next sought to explore a redesigned protocol for purifying SrtApneu that would 
maximize monomer content. After considering the data on heating to increase 
monomer concentration, a denaturing purification step followed by refolding was 
anticipated to provide a similar role as heating post-purification. Denaturation 
during purification would presumably eliminate any intermolecular contacts or 
domain swapping interactions that could hold together multiple units of the 
enzyme. Therefore, the original purification protocol was modified to include an 
initial denaturing purification with 8 M urea, where the E. coli were first lysed in a 
denaturing buffer, the protein purified from clarified lysate in denaturing buffer via 
IMAC, followed by the denatured sample being refolded with a non-denaturing 
buffer. Figure 27 shows the analysis of SrtApneu refolding via a rapid dilution of 
denatured SrtApneu into non-denaturing buffer (50 mM Tris pH 8.0, 150 mM NaCl) 
followed by an additional IMAC step to concentrate the refolded, soluble enzyme. 
Elution fractions from the rapid dilution refolding protocol were further purified by 
SE-FPLC to separate the sample into monomeric and oligomeric forms (Figure 
27). Analysis of SE-FPLC fractions by native PAGE analysis demonstrated that 
SrtApneu fractions with high monomer content could be isolated, however, a high 
relative concentration of enzyme was still trapped in the inactivated forms. 
Unfortunately, when refolded, monomeric SrtApneu tested in a model SML reaction 
continued to show diminished reactivity when compared to positive control 
reactions employing batch 1 SrtApneu (Figure 28). This was surprising, as we had 
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anticipated the pure monomer samples to perform as well as or better than batch 
1 SrtApneu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27.  (A) SDS-PAGE gel showing the purity of SrtApneu samples obtained 
from Ni-NTA purification after denaturing and refolding steps. (B) Native PAGE 
gel of SE-FPLC fractions 8-12 from the separation of SrtApneu purified by the rapid 
dilution protocol. A sample from lane 7 of the (A) was injected to produce the 
samples in this gel. (C) SE-FPLC trace of an injected sample from lane 7 in (A). 
The fractions shown in (B) come from this separation. 
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Figure 28. RP-HPLC analysis of a model SML reaction prepared with SE-FPLC 
purified monomeric SrtApneu from the denaturing purification protocol. This 
reaction was incubated for 24 hrs at room temperature before analysis. Only 
minimal processing of the substrate was observed, corresponding to 3.5% 
conversion of the substrate. 
 
To continue improvement of the SrtApneu preparations, we next explored 
the use of reducing agents to promote oligomer disassembly and to ensure that 
the active site cysteine residue remained in its fully reduced form. Preliminary 
experiments with dithiothreitol (DTT) had demonstrated some efficacy for 
restoring SrtApneu activity in vitro after a 22 hour incubation period at 37 oC 
(Figure 29), where SrtApneu incubated with 10 mM DTT produced more product 
(72% conversion) when compared to both unheated (21% conversion) and 
heated (47% conversion) samples. To build on this initial result, DTT was 
combined with prolonged heating at 37 oC. This resulted in even greater 
dissociation of oligomerized SrtApneu, in addition to increased intensity of the top 
band of the monomer doublet observed in native PAGE for SrtApneu (Figure 30). 
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While these native PAGE results were promising, the enzyme treated with these 
conditions failed to show any activity in vitro (Figure 29), despite the presence of 
significant monomer content in the enzyme sample. This prompted us to replace 
DTT with the non-sulfrous reducing agent tris(caboxyethyl)phosphine (TCEP).  
To our satisfaction, we observed that addition of 10 mM TCEP to SE-FPLC 
purified monomeric SrtApneu from the denaturing purification protocol greatly 
improved the percent conversion observed in model SML reactions by RP-HPLC 
analysis (Figure 31). Specifically, in the absence of TCEP, reactions reached 
only 3.5% conversion, whereas in the presence of TCEP reaction conversion 
increased to 60%. 
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Figure 29. RP-HPLC traces demonstrating the changes in product conversion 
produced by including 10 mM DTT during heat treatment of SrtApneu batch 3. 
Reactions were incubated at room temperature for 24 hrs before analysis. Heat-
treatment of SrtApneu for 22 hours at 37 °C increased substrate processing when 
10 mM DTT was added compared to samples which were not heated or heated 
without 10 mM DTT. Unfortunately, incubation of SrtApneu for 1 week with DTT at 
37 °C resulted in samples with diminished activity when compared to shorter 
heating times.  
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Figure 30. (A) Native PAGE gel demonstrating the effects of DTT on 22 hour 
incubations of batch 3 SrtApneu at 37 °C. (B) Native PAGE gel demonstrating the 
effects of DTT on 7 day incubations of batch 3 SrtApneu at 37 °C. Samples with 
DTT are denoted in the lane labels above. DTT appears to increase the intensity 
of the top band in the monomer doublet at the bottom of the gel, in addition to 
increasing overall monomer concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. RP-HPLC traces displaying the increase in SML activity with 10 mM 
TCEP added to SE-FPLC purified monomeric SrtApneu the denaturing purification 
after it was isolated. Reaction with TCEP was incubated 23 hrs at room 
temperature and the reaction without TCEP was incubated 24 hrs at room 
temperature before analysis. 
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 In an attempt to combine the incremental improvements gained by 
enzyme refolding and the addition of TCEP, we ultimately settled on a revised 
SrtApneu purification/refolding scheme in which TCEP was added to 1 mM in all 
purification and storage buffers. First, SrtApneu was expressed at 37 oC, followed 
by IMAC purification under denaturing conditions in the presence if 1 mM TCEP. 
IMAC fractions were then rapidly diluted in non-denaturing buffer containing 1 
mM TCEP, followed by an additional IMAC step to concentrate the enzyme. 
Enzyme samples purified under these conditions had higher relative monomeric 
concentration as compared to our original batch 2/3 materials that were neither 
refolded nor treated with TCEP (Figure 32). TCEP addition also increased the 
intensity of the upper band in the monomer doublet observed in native PAGE 
gels of SrtApneu samples, which we presume to be the active component of these 
enzyme preparations. Using SE-FPLC, enriched monomeric samples could be 
easily isolated (Figures 32 and 33). After isolation, we were pleased to observe 
that monomeric SrtApneu performed equally as well as the batch 1 positive control 
in model SML reactions (Figure 34), where 95% conversion was observed for 
the TCEP purified SrtApneu samples.  
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Figure 32.  (A) SDS-PAGE gel showing analysis of the purification steps of 
SrtApneu with TCEP as a buffer component. The sample in lane 5 of this gel was 
determined to be of good purity and concentration before rapid dilution and 
reconcentration to produce the sample in lane 8. (B) Native PAGE gel of 
reconcentrated SrtApneu after refolding by rapid dilution. When compared to 
batch 1 SrtApneu in lane 3, the band pattern appears very similar, including the 
high intensity of the upper band in the monomer doublet. (C) Native PAGE gel of 
the SrtApneu monomer fractions from SE-FPLC purification of a 1 mL injection of 
the sample in lane 1 of (B). 
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Figure 33. SE-FPLC traces from the purification of SrtApneu  by standard IMAC 
protocol separated at 0.75 mL/min (A) and with our adopted protocol using a 
denaturing purification step, refolding by rapid dilution, and reconcentration with 1 
mM TCEP in all buffers separated at 0.5 mL/min (B)	.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. RP-HPLC traces demonstrating the improved reactivity of SrtApneu 
purified with 1 mM TCEP in all buffers. The percent conversion after 24 hrs of 
incubation at room temperature is very similar to that of the reaction assembled 
with batch 1 SrtApneu, indicating the activity of these samples was fully recovered 
by this purification process.  
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2.2 Analysis of Potential Modes of SrtApneu Inactivation 
Given that we were able to separate monomeric SrtApneu from oligomeric 
SrtApneu, we next explored how the reactivity of oligomerized enzyme compared 
to the monomer. Using oligomeric SE-FPLC fractions in model SML reactions, 
we observed significantly less conversion of the peptide substrate when 
compared to monomeric fractions from the same purification (Figure 35). SDS-
PAGE and native PAGE analysis of these reactions confirmed that total enzyme 
content was identical between reactions, and further showed that the assembly 
state of the enzyme was not altered by the presence of SML reaction 
components. Overall, these results demonstrate that monomeric SrtApneu 
provided the best in vitro reactivity, while preparations enriched in enzyme 
oligomer were significantly less successful.  
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Figure 35. (A) RP-HPLC traces demonstrating the variability in reactivity 
between monomeric (blue) and oligomeric (green) preparations of TCEP purified 
SrtApneu. After 7 hours of incubation at room temperature, the reaction containing 
monomer reached 88% conversion, where as the oligomer reaction reached only 
58% conversion. (B) Equimolar loading of samples from the SrtApneu catalyzed 
peptide modification reactions in (A) separated through polyacrylamide gel 
electrophoresis. Gel (1) contains SDS and gel (2) does not. Identical samples 
were loaded in the lanes of each gel. Boxed lanes correspond to samples from 
reactions in HPLC traces of the same color at left.  
 
 
 With the knowledge that reducing conditions improved the activity of our 
SrtApneu preparations, we decided to evaluate the possibility of the active site 
cysteine oxidation to sulfenic acid, which has been observed in SrtApyogenes 
previously75. Commercially available, highly selective probes for sulfenic acid 
residues can be used to evaluate this type of oxidation in protein samples102, 103 
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HEPES buffer for the labeling reactions. A 10x molar excess of the sulfenic acid 
probe NO2-alkyne was added to these samples. After 24 hours of incubation at 
room temperature, positive control reactions assembled with 1.5 eq of H2O2 to 
batch 3 SrtApneu yielded an uncharged mass of 20427 Da upon deconvolution of 
the mass spectrum from the single peak in the sample (Figure 37). This exactly 
matches the expected mass of 20427 Da for NO2-alkyne combined with SrtApneu. 
The mass of SrtApneu was also found in the sample. Deconvolution of the mass 
spectrum from the single peak in the experimental reaction did not display the 
expected uncharged mass for the NO2-alkyne+SrtApneu adduct for batch 3 
SrtApneu. This result suggests that batch 3 samples, which function poorly in 
sortase mediated ligation reactions, do not suffer from sulfenic acid modifications 
to the active site cysteine.  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 36. (A) Structure of sulfenic acid probe NO2-alkyne used in the batch 3 
SrtApneu labeling reactions. (B) Mechanism of addition to a potential sulfenic acid 
modification in the active site of SrtApneu by the NO2-alkyne probe. This forms a 
stable thioether bond, allowing the change in mass to be easily recognized by 
mass spectrometry. 
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Figure 37. (A) Mass spectrum of the single peak found in labeling reactions for  
an unmodified sample of batch 3 SrtApneu after 24 hours of incubation with the 
NO2-alkyne sulfenic acid probe. (B) Deconvolution of the mass spectrum in (A), 
which returns an uncharged mass of 20144 Da as the major species, matching 
that of unmodified SrtApneu. (C) Mass spectrum of the single peak found in 
labeling reactions for a sample of batch 3 SrtApneu oxidized with 1.5 eq of H2O2 
and incubated for 24 hours with the NO2-alkyne sulfenic acid probe. (D) 
Deconvolution of the mass spectrum in (C) which shows two uncharged species 
in the sample. One species represents unmodified SrtApneu (20145 Da) and the 
other represents SrtApneu with the conjugated sulfenic acid probe NO2-alkyne 
(20427 Da). 
 
2.3 Conclusions and Future Directions. 
This section detailed the progress from inactive samples of SrtApneu to fully 
active samples of the enzyme. After evaluation of inactive SrtApneu samples 
showed a high degree of oligomerization, we began exploring methods of 
reducing the assembled forms of the enzyme. While heating samples of purified 
SrtApneu returned activity to the samples and removed most of the oligomerized 
enzyme, we believed more efficient procedures could be developed to achieve 
the same result. By adding a denaturing step to the purification, we were able to 
decrease some oligomerization in the SrtApneu samples. SE-FPLC purification of 
SrtApneu after disassembly of oligomers proved to be an effective method to 
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produce monomeric enzyme stocks. While we expected this to improve the 
catalytic activity of the preparations, activity was only regained after addition of 
the reducing agent TCEP to the purification buffer. The addition of TCEP to the 
total purification also improved the monomer:oligomer ratio in the samples, which 
afforded more available monomer for isolation by SEC. This purification 
procedure has now consistently yielded active batches of enzyme over multiple 
expressions in the lab.  
As noted previously, inclusion of a reducing agent in the SrtApneu buffers 
modifies the intensity of an interesting doublet that appears in monomer region of 
native PAGE gels. Previously, SrtApyogenes has been shown to have an altered 
conformation upon oxidation of the active site cysteine to sulfenic acid.75 We 
hypothesize that reducing conditions reverse some form of oxidation in SrtApneu, 
which ultimately leads to differences in protein conformation. Both oxidized and 
unoxidized forms of the protein could be present in solution, creating two 
alternative conformers which would appear as separate bands in native PAGE 
analysis. Additionally, based on the observation that reducing conditions diminish 
the presence of oligomerized SrtApneu in solution, oxidation of the enzyme may 
facilitate a conformation that is more susceptible to interactions with other 
enzyme units in solution.  
This thesis also marks the first account of oligomerized SrtApneu, along 
with the first attempts to understand the cause and dissolution of the assembled 
enzyme. The oligomerization of this SrtA homolog appears to be driven by highly 
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favorable interactions as determined by dilution experiments of these samples, 
where no effect on oligomer concentration in solution was observed. 
Interconversion between the dimer and monomer states of the enzyme appears 
to have a high activation barrier, as it can only be disrupted by heating or 
complete unfolding of the enzyme samples. Further, recovered monomeric 
SrtApneu does not appear to rapidly re-oligomerize, also supporting the hypothesis 
of a high activation barrier between the two states. Hypothetically, this behavior 
could be attributed to domain swapping of SrtApneu monomers, evidence of which 
comes from the structure of SrtApneu in a domain swapped conformation (PDB ID: 
4O8L).  
Three dimensional domain swapping is an interaction between two or 
more identical protein monomers, where one or more domains or segments of 
the monomers rotate out of the core structure and take the place of the same 
amino acids in the opposite monomer.104 This interaction generally results in 
identical interactions in both the closed monomer and domain swapped forms of 
the proteins, but may also result in additional favorable interactions within the 
domain swapped oligomers.104 In vivo, the open state that propagates 
oligomerization is most likely generated when monomers are transiently exposed 
to denaturing conditions, such as an acidic compartment within the cell.104 The 
open monomers become free to form domain swapped interactions, which 
creates the oligomerized forms of the protein. The process of converting between 
either monomer or oligomer most likely has a high energy barrier, as favorable 
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contacts must be broken to rotate protein domains out of the core structure.104 
This allows for different states of the same protein to be present in solution. 
Domain swapping has been simulated in vitro to afford not only dimeric 
proteins,105 but also trimeric106, 107 and higher order107, 108 assembly states, which 
suggests this phenomenon could produce the full range of oligomers seen in 
samples of SrtApneu. These observed qualities of domain swapped proteins, in 
addition to the domain swapped structure of SrtApneu, align with the data 
presented in this thesis, and suggests that SrtApneu undergoes domain swapping 
to form oligomerized enzyme. It would be beneficial to perform experiments 
probing the dissociation constant of the monomer-dimer equilibrium, as these 
could aide our understanding of the strength of the association between 
monomers. Additionally, more rigorous analysis of alternative purification 
conditions could be done to aide in our understanding of the mechanism of 
domain swapping in SrtApneu, while also potentially simplifying purification of the 
enzyme.  
Future directions for this aspect of the project revolve around 
crystallization of the monomeric preparations of SrtApneu. While trials towards this 
have already been undertaken, more work is needed to develop the conditions 
necessary for crystal growth.  
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Chapter 3. Design and Synthesis of Ketomethylene-based 
Substrate Analogs 
 
3.1 Design of Ketomethylene Isosteres  
Concurrent with our efforts to produce reliable preparations of active 
SrtApneu suitable for structural characterization, we have also undertaken the 
synthesis of substrate mimics that can be covalently anchored in the enzyme 
active site. To this end, we have designed substrate analogs in which the scissile 
amide bond of standard sortase substrates is replaced with a non-cleavable 
ketomethylene dipeptide isostere (Figure 38).  
 We anticipated that ketomethylene isosteres of SrtApneu substrates would 
serve as non-cleavable analogs for obtaining a structure of the substrate bound 
state. The proposed ketomethylene analogs for this purpose have been 
previously used as potent inhibitors of serine proteases,109 which share 
mechanistic characteristics with sortases.	We propose that the inserted ketone 
will be able to form a covalent bond with the active site cysteine which will be 
further stabilized by the remaining contacts present in standard sortase 
substrates. The synthetic processes laid out here allow for variability in the 
substitution present at either site in the ketomethylene-linked dipeptide. Further, 
the methods for developing these molecules allow for the production of 
fluorenylmethyloxycarbonyl (Fmoc) protected N-termini109, 110, affording products 
ready for incorporation into peptides via solid phase synthesis.  
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Figure 38. Comparison of a normal peptide substrate and a substrate with a 
ketomethylene linkage inserted between the 4th and 5th positions of the sorting 
sequence. The red box denotes the methylene substitution in the amide bond. R1 
and R2 can be any amino acid functional group and are only limited by the 
synthetic process.  
 
3.2 Preliminary Ketomethylene Analog Synthesis and Testing  
To evaluate the ability of a ketomethylene-linked peptide interacting with 
the active site of SrtApneu, we first synthesized a substrate analog incorporating 
commercially available 5-aminolevulinic acid. While this unit was not anticipated 
to be optimal with respect to enzyme recognition due to the lack of sidechains in 
position 4 and 5 of the substrate mimic, we elected to start with this compound as 
a proof of concept study. As described by Rogers et al.,111 synthesis began with 
solution-phase acylation of 5-aminolevulinic acid with the N-hydroxysuccinamide 
ester of Fmoc-Ala-OH (Fmoc-Ala-OSu) to produce an Fmoc-protected 
ketomethylene tripeptide analog of Ala-Gly-Gly, hereafter referred to as Fmoc-
A[G(keto)G]. This material was then used in solid-phase peptide synthesis 
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(SPPS) to generate a full size substrate analog (1).112 The identity of 1 was 
verified by ESI-MS, the material was purified to homogeneity by RP-HPLC, and 
the peptide was lyophilized prior to use (Figure 39).  
 
 
Figure 39. Synthesis and analysis of the preliminary ketomethylene substrate 
analog using the AG(keto)G block to install a non-cleavable linkage between the 
4th and 5th residues. 
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be expected for the model reaction system used in Chapter 2 of this thesis. 
Analysis via RP-HPLC suggested that analog 1 was able to act as an inhibitor, 
reducing reaction conversion at as low as 0.1 eq in relation to the Abz-LPATA-
GK(Dnp) substrate. Reaction progress was diminished by less than 50% at 1 eq 
of inhibitor, and reached as little as 30% relative conversion at 5 eq. Aside from 
the single expected peak from the inhibitor itself, no additional peaks developed 
when the inhibitor was added, demonstrating that it was not being cleaved by the 
enzyme. Overall, these data indicated that ketomethylenes can serve as non-
cleavable isosteres in SML, which in turn could be useful for structural 
characterization of enzyme/substrate complexes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. RP-HPLC analysis for the inhibition of transpeptidation by 
ketomethylene substrate analog 1. These reactions were assembled with 
undiluted, 7 day heat-treated SrtApneu and allowed to incubate at room 
temperature for 24 hrs before quenching with N-ethylmaleimide (NEM) for 
analysis by HPLC. 
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3.3 Second Generation Design of Ketomethylene Substrate Analogs  
 Having successfully shown that 1 was able to impede an in vitro SML 
reaction, we next sought to design derivatives with substituents that mimic the 
side chains of position 4 and 5 in the sortase substrate motif. Ideally, these 
substituents would match the side chains of threonine and alanine residues for 
optimal structural overlap with the known LPATA substrate of SrtApneu. However, 
for synthetic ease we opted to focus on simple methyl groups, which would mirror 
the side chains of alanine residues. While it was known from previous work in our 
group that alanine was well tolerated in position 5 (see Figure 4), we wanted to 
verify that alanine was accepted at position 4 or in combination with alanine at 
position 5. To test this, peptide substrates displaying LPATAG, LPAAGG, and 
LPAAAG were prepared via SPPS and tested in model SML reactions. As shown 
in Figure 41, all variants were accepted by SrtApneu, however, the LPAAGG (53% 
conversion) and LPAAAG (20% conversion) substrates were not processed to 
the same extent as LPATAG (88% conversion). Nonetheless, these results 
suggested that simple methyl groups in positions 4 and 5 should suffice for 
enzyme recognition. Based on these results, two additional ketomethylene-linked 
peptide isosteres were designed to serve as substrate analogs of LPAAG (2) and 
LPAAA (3) (Figure 42). 
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Figure 41. Analytical RP-HPLC traces showing the variable activity of SrtApneu 
with substrates differing from its preferred sequence of LPATA. These reactions 
were incubated for 24 hrs at room temperature using a monomeric fraction of 
SrtApneu from FPLC purification with TCEP. 
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Figure 42. Structures of the next generation of ketomethylene-based substrate 
analogs for SrtApneu. 2 represents the ketomethylene analog of LPAAG and 3 
represents the analog of LPAAA. These pseudopeptides will include substitution 
at the amino acid positions surrounding the non-cleavable ketomethylene linkage 
used to replace the scissile peptide bond. 
 
3.4 Progress Toward Synthesis of Substituted Ketomethylene Isosteres  
 To access structures 2 and 3, we began with a procedure from Budnjo et 
al.109 towards synthesizing the ketomethylene linked dipeptide isosteres A(keto)G 
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Treatment with TFA was anticipated to remove the t-butyl ester protecting 
groups, followed by in situ decarboxylation to generate the desired keto 
methylene building blocks 7a or 7b. 
 
 
 
 
 
 
 
Scheme 1. Overview of the synthetic scheme from Budnjo et al.109 using an 
Fmoc-protected amino acid starting material.  
 
 
  
  
Scheme 2. Synthesis of the Fmoc-protected ketoester  
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procedure from Mathieu et al.110 involving catalytic 4-dimethylaminopyridine 
(DMAP) to activate the amino acid and excess t-butyl acetate to generate the 
enolate, was substituted for the procedure by Budnjo et al. (Scheme 2) which 
enabled us to synthesize the desired product 5 in 27% yield. With the ketoester 
in hand, we then prepared triflates 4a (72% yield) and 4b (73% yield) using triflic 
anhydride and 2,6-lutidine (Scheme 3) according to the procedure from Budnjo 
et al.  
 
 
 
 
 
Scheme 3. Synthesis of triflate compounds from t-butyl esters with varying 
substitution. 
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reaction turnover by including slight excesses of NaH only resulted in greater 
deprotection of the Fmoc-Ala t-butyl ketoester.  
 
 
 
 
 
 
Scheme 4. Synthetic process to generate the fully protected ketomethylene  
 
After these many failed attempts at using the Fmoc-protected starting 
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protected ketoester 8 (Scheme 6) which was easily purified from the extracted 
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Scheme 5. Overall synthetic scheme to produce Fmoc-protected ketomethylene 
dipeptide isosteres using Boc amino acids as starting materials. 
 
 
 
 
Scheme 6. Synthesis of the Boc-protected ketoester  
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resonance (NMR) spectroscopy of this product was too convoluted to accurately 
assign peaks, however, LC-ESI-MS was able to confirm the mass of the Na+ 
adduct of this material. 
 
 
 
 
 
Scheme 7. Synthesis of the fully protected Boc-ketomethylene. 
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Scheme 8. Synthesis of disubstituted Fmoc protected ketomethylene  
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4. Experimental 
Protein Expression and Purification 
Full sequence of SrtApneu protein used in this study: 
MESSHHHHHHAVLTSQWDAQKLPVIGGIAIPELEMNLPIFKGLDNVNLFYGAGT
MKREQVMGEGNYSLASHHIFGVDNANKMLFSPLDNAKNGMKIYLTDKNKVYTY
EIREVKRVTPDRVDEVDDRDGVNEITLVTCEDLAATERIIVKGDLKETKDYSQTS
DEILTAFNQPYKQFY 
 
Expression and purification of SrtApneu batches 1 and 3. The SrtApneu 
expression vector was obtained by commercial gene synthesis in a pJ414 
expression vector from DNA2.0 (Menlo Park, CA). The plasmid containing 
SrtApneu was transformed into BL21 (DE3) chemically competent E. coli by heat 
shock. Following addition of 1 mL Luria-Bertani (LB) broth, the cells were 
incubated for 1 hour at 37 oC with shaking. Cells were the plated on LB-agar 
plates containing 100 µg/mL ampicillin, and incubated overnight at 37 oC. A 
single isolated colony was selected and used to inoculate 50 mL of LB broth 
(containing 100 µg/mL ampicillin), which was then placed in a 37 oC shaking 
incubator to grow overnight. Roughly 30 mL of this starter culture were then 
added to 1 L of LB broth (containing 100 µg/mL ampicillin) to initiate large-scale 
growth. This culture was allowed to grow to an OD600 reading of 0.7-0.8 at 37 oC 
in a shaking incubator. Protein expression was then induced by the addition of 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. 
Cells remained at 37 oC with shaking for 3 hours to express SrtApneu, and were 
then isolated by centrifugation at 10000xg. The cell pellets were then 
resuspended in 30 mL lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM 
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EDTA), treated with lysozyme at a final concentration of 10 mg/mL, and 
incubated at room temperature for 1 hour. This mixture was sonicated for 2, 30 
second intervals at 50% output and the lysate was then clarified by centrifugation 
at 20000xg. This clarified lysate was added to a 5 mL His-Bind (Thermo-Fisher) 
Ni-NTA column equilibrated in wash buffer (20 mM Tris pH 8.0, 150 mM NaCl, 20 
mM imidazole). Bound protein was further washed with 10 column volumes of 
wash buffer, then eluted in two, 1 column volume aliquots of elution buffer (20 
mM Tris pH 8.0, 150 mM NaCl, 300 mM imidazole). These preparations were 
dialyzed against dialysis buffer (20 mM Tris pH 8.0, 150 mM NaCl) to remove 
imidazole. Glycerol was added to 10% v/v before the samples were stored at -80 
oC. Collected fractions were analyzed by native and SDS-PAGE. The activity of 
these samples was evaluated by model sortase-mediated ligation (SML) 
reactions with the known substrate LPATA. Were described, FPLC analysis of 
these samples was performed Samples of SrtApneu were subjected to various 
incubation temperatures for various times before purification and analysis on an 
NGC FPLC system (Bio-Rad) by size-exclusion chromatography using an Enrich 
SEC 70 column (Bio-Rad) with 50 mM Tris pH 8.0, 150 mM NaCl buffer as the 
eluent at 0.5 or 0.75 mL/min. Variable temperature expressions described in 
Chapter 2 were carried out by this procedure, except during expression, where 
the temperature was adjusted to 16 or 25 °C. 
Expression and purification of SrtApneu batch 2. The SrtApneu expression 
vector was obtained by commercial gene synthesis in a pJ414 expression vector 
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from DNA2.0 (Menlo Park, CA). The plasmid containing SrtApneu was transformed 
into BL21 (DE3) chemically competent E. coli by heat shock.. Following addition 
of 1 mL LB broth, the cells were incubated for 1 hour at 37 oC with shaking. Cells 
were the plated on LB-agar plates containing 100 µg/mL ampicillin, and 
incubated overnight at 37 oC. A single isolated colony was selected and used to 
inoculate 50 mL of LB broth (containing 100 µg/mL ampicillin), which was then 
placed in a 37 oC shaking incubator to grow overnight. Roughly 30 mL of this 
starter culture were then added to 1 L of LB broth (containing 100 µg/mL 
ampicillin) to initiate large-scale growth. This culture was allowed to grow to an 
OD600 reading of 0.7-0.8 at 37 oC in a shaking incubator. Protein expression was 
then induced by the addition of IPTG to a final concentration of 1 mM. Cells 
remained at 37 oC with shaking for 3 hours to express SrtApneu, and were then 
isolated by centrifugation at 6000xg. The cell pellets were then resuspended in 
30 mL lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA), treated 
with lysozyme at a final concentration of 10 mg/mL, and incubated at RT for 1 
hour. This mixture was sonicated for 2, 30 second intervals at 50% output and 
the lysate was then clarified by centrifugation at 18000xg. This clarified lysate 
was added to 5 mL of His-Bind (Thermo-Fisher) Ni-NTA resin in a conical tube 
and imidazole was added to 20 mM before the contents were mixed for 30 min at 
room temperature. The slurry was centrifuged at 700xg for 2 min and the 
supernatant removed. The resin pellet was resuspended in 25 mL of wash buffer 
(20 mM Tris, pH 8.0, 150 mM NaCl, 20 mM imidazole) and transferred to an 
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empty column. After settling, the wash buffer was drained to the resin bed and 25 
mL of wash buffer was passed through the column. Bound protein was then 
eluted in two, 5 mL aliquots of elution buffer (20 mM Tris pH 8.0, 150 mM NaCl, 
300 mM imidazole). To further purify the eluted protein, elution 1 of the initial 
purification was diluted 10-fold with dilution buffer (20 mM Tris, pH 8.0, 150 mM 
NaCl) and recirculated through a 5 mL Ni-NTA column. The bound protein was 
further washed with 10 mL of wash buffer and eluted in 3, 5 mL portions of 
elution buffer. The loading flowthrough of this purification was also 
reconcentrated using a 5 mL Ni-NTA column. After loading, the bound protein 
was washed with 15 mL wash buffer and and eluted in two, 5 mL aliquots of 
elution buffer. These preparations from the 2nd and 3rd purification steps were 
dialyzed against dialysis buffer (20 mM Tris pH 8.0, 150 mM NaCl) to remove 
imidazole. Glycerol was added to 10% v/v before the samples were stored at -80 
oC. Collected fractions were analyzed by native and SDS-PAGE. The activity of 
these samples was evaluated by model sortase-mediated ligation (SML) 
reactions with the known SrtApneu known substrate LPATA.  
SrtApneu expression, non-reducing/denaturing purification and refolding. A 
50 uL aliquot of BL21(DE3) cells in 50% glycerol containing the plasmid for 
SrtApneu was added to 50 mL of LB broth containing 100 µg/mL ampicillin and 
incubated with shaking at 37 oC overnight. Roughly 30 mL of culture were then 
added to one 1 L of LB broth containing 100 µg/mL ampicillin to initiate large-
scale growth. This culture was allowed to grow to an OD600 reading of 0.7-0.8 at 
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37 oC in a shaking incubator before induction with 1 mM IPTG. Cells remained at 
37 oC with shaking for three hours to express SrtApneu, and were then isolated by 
centrifugation at 6000xg. Cell pellets were resuspended in 30 mL denaturing lysis 
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 8 M urea). The 
resuspended cells were sonicated for 2, 30 second intervals at 50% power output 
and the lysate was clarified by centrifugation at 18000xg. This clarified lysate was 
added to a 5 mL His-Bind resin (Thermo-Fisher) column pre-equilibrated in 
denaturing wash buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 mM imidazole, 8 
M urea). Bound protein was washed with 10 column volumes of wash buffer and 
then eluted in two, 1 column volume portions of denaturing elution buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 300 mM imidazole, 8 M urea). The first eluted fraction 
was then rapidly diluted by addition to a 100x volume of dilution buffer (50 mM 
Tris pH 8.0, 150 mM NaCl). This material was then recirculated through a 5 mL 
Ni-NTA column equilibrated in wash buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 
mM imidazole). Bound protein was further washed with 10 column volumes of 
wash buffer, then eluted in two 1 column volume aliquots of elution buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 300 mM imidazole). Collected fractions were 
analyzed by native and SDS-PAGE. SrtApneu monomer was further purified on an 
NGC FPLC system (Bio-Rad) by size-exclusion chromatography using an Enrich 
SEC 70 column (Bio-Rad) with 50 mM Tris pH 8.0, 150 mM NaCl buffer as the 
eluent at 0.5 mL/min. Monomeric protein fractions were pooled, and if necessary, 
concentrated using centrifugal concentrators. The activity of these samples was 
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evaluated by model sortase-mediated ligation (SML) reactions with the known 
substrate LPATA. These samples were stored at 4 oC or -20 oC. 
SrtApneu expression, reducing/denaturing purification and refolding. The 
optimized procedure for the expression and purification of SrtApneu is identical to 
that for the non-reducing/denaturing purification described above, with the 
exception of 1 mM TCEP being included in all buffers used. 
Evaluation of protein concentration. UV-vis spectroscopy for determining 
concentrations of the prepared samples was performed on a NanodropTM ND-
1000 spectrophotometer (Thermo Scientific) at 280 nm using 17,440 M-1cm-1 as 
the estimated molar extinction coefficient from analysis of the protein sequence 
by ExPasy ProtParam. 
Protein LC-ESI-MS analysis.  Liquid chromatography electrospray 
ionization mass spectrometry (LC-ESI-MS) was performed using a Dionex 
Ultimate 3000 HPLC system (Thermo Scientific) connected to an expression L 
high performance compact mass spectrometer (Advion, Inc.) through analytical 
scale separations using a Phenomenex Kinetex 2.6 µm, 100 Å C4 column (2.0 x 
100 mm) with the method (Method A): MeCN (0.1% formic acid)/95% H2O, 5% 
MeCN (0.1% formic acid) mobile phase. Flow rate = 0.3 mL/min. Gradient = 10% 
MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN (0.5-6.0 min), hold 90% MeCN 
(6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), re-equilibrate to 10% 
MeCN (7.1-10.0 min). Data analysis was done in Advion Data Express software 
version 3.0. Mass spectrum deconvolution was achieved through a max entropy 
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goodness of fit algorithm to determine uncharged masses of samples. 
 
Analysis of SrtApneu Transpeptidation Activity 
Evaluation of enzymatic activity with various peptides containing the 
fluorophore-quencher pair 2-aminobenzoyl (Abz) and 2,4-dinitrophenol (Dnp) 
were carried out at room temperature with the concentrations shown in the table 
below for the model sortase mediated ligation reactions. Specific additives are 
noted where necessary within the presentation of the data. Reactions were 
prepared by combining all components shown in Table 4 except sortase, which 
was added to initiate the reaction. Conversion was analyzed by UV/VIS analysis 
of analytical RP-HPLC using a Dionex Ultimate 3000 HPLC system (Thermo 
Scientific) with a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (3.0 x 100 
mm) with the method (Method B): MeCN (0.1% TFA)/H2O (0.1% TFA) mobile 
phase. Flow rate = 0.7 mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN 
to 90% MeCN (0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 90% MeCN to 10% 
MeCN (7.0-7.1 min), re-equilibrate to 10% MeCN (7.1-10.0 min).  
Percent conversion was calculated by dividing the area of the product 
peak by the addition of total 2,4-DNP containing reactant and product peak areas 
at 330 nm. 
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Table 2. Reaction conditions for sortase mediated ligation. Water was added to 
50 uL total reaction volume unless otherwise noted. 
Stock Solution Reaction Concentration 
Buffer (500 mM Tris, pH 7.5, 150 mM 
NaCl) 
50 mM Tris, pH 7.5, 150 mM NaCl 
Substrate (1:1 DMSO/Water) (0.5-4 mM) 40 or 100 µM 
Nucleophile (Water) (10 mM) 10 mM 
SrtApneu (50-300 µM) 10 µM 
 
Peptide Synthesis 
All chemicals were obtained from commercial sources and were used 
without further purification. Reactions were performed in flame-dried glassware 
under argon atmosphere. HPLC purification and analysis was performed using a 
Dionex Ultimate 3000 HPLC system. LC-ESI-MS was performed with API 2000 
Triple Quadrupole mass spectrometer (Applied Biosystems) and an Agilent 1100 
HPLC system equipped with a Phenomenex Aeris Widepore 3.6 µm 200 Å XB-
C8 column (4.6 x 150 mm). All samples were analyzed using the following 
method (Method C): H2O (0.1% formic acid) / organic (95% MeCN, 5% 
isopropanol, 0.1% formic acid) mobile phase. Flow rate = 1.25 mL/min. Gradient 
= 10% organic (0.0-1.0 min), 10% organic to 90% organic (1.0-10.0 min).  
Analytical separations for UV/vis analysis were performed with a 
Phenomenex Kinetex 2.6 µm, 100 Å C18 column (3.0 x 100 mm) with the method 
(Method B): MeCN (0.1% TFA)/H2O (0.1% TFA) mobile phase. Flow rate = 0.7 
mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN (0.5-6.0 
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min), hold 90% MeCN (6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), re-
equilibrate to 10% MeCN (7.1-10.0 min).  
Semi-preparative separations for purification of peptides were performed 
with a Phenomenex Luna 5 µm 100 Å C18 column (10 x 250 mm) fitted with a 
Phenomenex SecurityGuard SemiPrep Guard cartridge (10 mm ID). Purification 
separations were carried out with the one of the following methods: (Method D): 
MeCN (0.1% TFA)/H2O (0.1% TFA) mobile phase. Flow rate = 0.5 to 4.0 mL/min 
(0.0-2.0 min), hold 4.0 mL/min (2.0-17.01 min), 4.0 to 0.5 mL/min (17.01-19.0 
min). Gradient = 20% MeCN (0.0-2.0 min), 20% MeCN to 90% MeCN (2.0-15.0 
min), hold 90% MeCN (15.0-17.0 min), 90% MeCN to 10% MeCN (17.0-17.01 
min), re-equilibrate to 10% MeCN (17.01-19.0 min) or (Method E):  MeCN (0.1% 
TFA)/H2O (0.1% TFA) mobile phase. Flow rate = 0.5 to 4.0 mL/min (0.0-2.0 min), 
hold 4.0 mL/min (2.0-17.01 min), 4.0 to 0.5 mL/min (17.01-19.0 min). Gradient = 
30% MeCN (0.0-2.0 min), 30% MeCN to 60% MeCN (2.0-15.0 min), 60 to 90% 
MeCN (15.0-15.01 min), hold 90% MeCN (15.01-17.0 min), 90% MeCN to 10% 
MeCN (17.0-17.01 min), re-equilibrate to 10% MeCN (17.01-19.0 min) 
Solid-phase peptide synthesis. Peptides were synthesized on a 0.1 mmol 
scale using rink amide MBHA resin. Deprotection was achieved by washing with 
20% piperidine/NMP (10 mL, 2x, 20 min) and was followed by washing with NMP 
(10 mL, 3x, 10 min). To the deprotected resin, a mixture containing an Fmoc 
protected amino acid (0.3 mmol), HBTU (0.3 mmol) and DIPEA solvated in NMP 
was added, which was left to incubate for 1 hr-24 hrs at room temperature with 
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shaking. Unreacted coupling components were removed and the resin washed 
with NMP (10 mL, 3x, 10 min) before repetition of this process to couple all 
amino acids. Acetyl capping of the N-terminus was achieved by combining acetic 
anhydride (0.3 mmol), DIPEA, and NMP, which was added to the resin to couple 
for 2 hrs. Each peptide generated as a substrate for SML reactions contained the 
2-aminobenzoyl (Abz) and 2,4-dinitrophenyl (Dnp) fluorphore-quencher pair to 
simplify analysis by UV/vis spectroscopy. Dnp was added as a conjugate to ε-
amine of a lysine side chain [Fmoc-K(Dnp)]. After completion of the peptide, the 
resin was washed with DCM (10 mL, 3x, 10 min) and incubated with cleavage 
solution (9.5 mL TFA, 0.25 mL H2O, 0.25 mL TIPS) for 30 min (5 mL, 2x). The 
cleaved peptide was collected and concentrated via rotary evaporation before 
being precipitated into dry ice-cooled diethyl ether. The precipitate was 
centrifuged at 5000xg for 5 min and the ether discarded to afford a peptide pellet, 
which was dried under vacuum for 24 hrs. Peptides were solubilized by a mixture 
of water and acetonitrile that was variable based on the amino acid composition. 
Purification from this state was achieved by RP-HPLC with either method D or E 
and the molecular mass of the peptides verified via LC-ESI-MS method C. 
Peptides were lyophilized and resolubilized in 1:1 water/DMSO or DMSO to 
produce stock solutions for use in reactions, which were further analyzed for 
purity by HPLC analysis using method B. Concentrations were estimated by 
UV/Vis spectroscopy on a NanodropTM ND-1000 spectrophotometer (Thermo 
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Scientific) at 365 nm using the molar extinction coefficient 17,400 M-1cm-1 for the 
Dnp chromophore. 
 
Synthesis of Small Molecules 
All chemicals were obtained from commercial sources and were used 
without further purification. NMR spectra were collected with a Brüker Avance 
spectrometer at 500 MHz for 1H. FID processing and figure generation was done 
using Mestrelab MestReNova software version 10.0.2-15465. Reactions were 
performed in flame-dried glassware under argon atmosphere. HPLC purification 
and analysis was performed using a Dionex Ultimate 3000 HPLC system. LC-
ESI-MS was performed with a Dionex Ultimate 3000 HPLC system connected in 
line to an expression L high performance compact mass spectrometer (Advion, 
Inc.). Analytical separations for MS analysis of synthetic products were achieved 
with a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (2.0 x 100 mm) with the 
method (Method F): MeCN (0.1% formic acid)/95% H2O, 5% MeCN (0.1% formic 
acid) mobile phase. Flow rate = 0.4 mL/min. Gradient = 5% MeCN (0.0-0.5 min), 
5% MeCN to 90% MeCN (0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 90% 
MeCN to 10% MeCN (7.0-7.1 min), re-equilibrate to 10% MeCN (7.1-12.0 min).  
Ala-5-ALA synthesis. Fmoc-Ala-OSu (1.2 g, 3.0 mmol) and 5-
aminolevulinic hydrochloride (0.50 g, 3.0 mmol) were added to dry THF (40 mL) 
and cooled to 0 oC. DIPEA (0.52 mL, 3.0 mmol) was dissolved in dry THF (20 
mL) and then added dropwise to the stirred suspension across 120 minutes. The 
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reaction was allowed to return to room temperature and stirred for 23 days after 
which the mixture was filtered, concentrated by rotary evaporation and dissolved 
into ethyl acetate (50 mL). The organic layer was washed with water (3x, 50 mL) 
and extracted into 5% NaHCO3 (3x, 25 mL). The aqueous layer was then 
collected and acidified with 1M HCl until no further precipitation occurred. This 
heterogeneous mixture was then extracted with ethyl acetate (3x, 75 mL) and 
dried over MgSO4. The solvent was removed by rotary evaporation to produce a 
white solid which was used without further purification. IUPAC Name: (S)-5-(2-
((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-oxopentanoic acid 
(0.72 g, 57% yield). 1H NMR (500 MHz, D6-DMSO): δ 12.10 (br. s, 1H), 8.13 (m, 
1H), 7.88 (d, J = 7.6, 2H), 7.72 (t, J = 7.7, 2H), 7.55 (d, J = 7.7, 1H), 7.40 (t, J = 
7.3, 2H), 7.32 (t, J = 7.5, 2H), 4.26-4.18 (m, 3H), 4.11-4.05 (m, 1H), 3.98-3.87 (m, 
2H), 2.63 (t, J = 6.2, 2H), 2.39 (t, J = 6.5, 2H), 1.23 (d, J = 7.2, 3H). 
Ketoester synthesis. Boc-Ala-OH (7.0 mmol) was dissolved in dry THF (20 
mL), to which CDI (1.08 g, 7.7 mmol) was added under stirring in three portions, 
resulting in bubble formation. Within five minutes of CDI addition, 5 mol% DMAP 
was added to the reaction mixture. This was left to stir for one hour, during which 
t-butyl acetate (4.1 mL, 28.7 mmol) was added dropwise to 1 M LiHMDS (28 mL, 
28 mmol)  in THF (28 mL) at -78 oC under stirring across 5-10 minutes. This 
reaction was left to stir for 10-15 min at -78 °C, removed from cooling and stirred 
at room temperature for 10 minutes, then cooled to -78 °C and stirred for 20 
additional minutes before the activated amino acid was added dropwise at -78 °C 
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across 10 minutes. The combined reaction was allowed to stir for 1.5 hrs at -78 
°C before being quenched with 10% w/v citric acid (50 mL). The mixture was 
extracted with ethyl acetate (2x, 30 mL), washed with sat. NaHCO3 (30 mL) and 
sat. NaCl (3x, 30 mL) before being dried over MgSO4. After concentration by 
rotary evaporation, the crude product was purified by flash column 
chromatography (1:3 EtOAc/n-hexane) yielding the product as a white solid. 
IUPAC Name: tert-butyl (S)-4-((tert-butoxycarbonyl)amino)-3-oxopentanoate 
(1.44 g, 72% yield). 1H NMR (500 MHz, CDCl3): δ 5.19-5.09 (m, 1H), 4.42-4.32 
(m, 1H), 3.49, 3.42 (ABq, JAB = 16, 2H), 1.46 (s, 9H), 1.44 (s, 9H), 1.35 (d, J = 
7.2, 3H).  
Triflate synthesis. To a solution of t-butyl R-lactate or t-butyl 2-
hydroxyacetate (5.0 mmol) in dry DCM (20 mL) was added 2,6-lutidine (0.87 mL, 
5.0 mmol). The mixture was cooled to 0 °C and triflic anhydride (1.18 mL, 5.0 
mmol) was added dropwise across 70 minutes, during which the color changed 
to light red then orange. After stirring for 1 hour at 0 °C, the reaction mixture was 
diluted with n-hexane (100 mL), washed with 1:3 1M HCl/sat. NaCl (3x, 50 mL), 
and dried over MgSO4. The extract was concentrated by rotary evaporation and 
dried under vacuum to afford the product as a red or orange oil which was used 
without further purification. 
IUPAC Name: tert-butyl (R)-2-(((Trifluoromethyl)sulfonyl)oxy)propanoate 
(1.01 g, 73% yield). 1H NMR (500 MHz, CDCl3): δ 5.09 (q, J = 7.0, 1H), 1.66 (d, J 
= 7.0, 3H), 1.50 (s, 9H). 1H NMR consistent with previously reported spectra.109 
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IUPAC Name: tert-butyl 2-(((Trifluoromethyl)sulfonyl)oxy)acetate (0.96 g, 
72% yield). 1H NMR (500 MHz, CDCl3): δ 4.78 (s, 2H), 1.51 (s, 9H).  
Ketomethylene synthesis. Boc-Ala ketoester (0.50 g, 1.7 mmol) was 
solvated in dry DCM (10 mL) and added dropwise to a stirred suspension of NaH 
(60% in mineral oil, 0.21 g, 5.2 mmol) in dry THF (10 mL) at -5 °C. This mixture 
was allowed to stir for 20 min, after which triflate (1.74 mmol) in dry THF (5 mL) 
was added at -5 °C. The resulting contents were allowed to stir overnight at room 
temperature before being quenched with 10% w/v citric acid (20 mL). The 
quenched reaction was extracted with EtOAc (3x, 20 mL) washed with sat. NaCl 
(60 mL), and dried over MgSO4 before being concentrated via rotary evaporation 
to yield a yellow oil. This residue was purified by flash column chromatography 
with 1:3 EtOAc/hexane and the desired product fractions identified, pooled, and 
concentrated by rotary evaporation. This residue was solvated in 10% TFA/DCM 
and allowed to stir overnight at room temperature. After concentrating the 
resulting mixture by rotary evaporation, the residue was dissolved in DCM and 
reconcentrated by rotary evaporation (3x) after which the remaining solvent was 
removed in vacuo. Data for protected ketomethylene: IUPAC Name: di-tert-butyl 
2-((tert-butoxycarbonyl)-L-alanyl)succinate LC-ESI-MS: m/z calculated (M+Na+): 
424.5, observed: 424.3. 
Fmoc protection. The vacuum dried deprotected ketomethylene was 
dissolved in 1:1 water/MeCN (10 mL) and DIPEA (0.91 mL, 3 eq) was 
administered to bring the solution to pH ~8. Fmoc-OSu (0.59 g, 1 eq.) was added 
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and allowed to react for 24 hours before the addition of 10 mL of 1 M HCl, which 
formed a precipitate. The reaction was extracted into EtOAc (3x, 10 mL), washed 
with sat. NaCl (30 mL) and dried over MgSO4 before being concentrated under 
rotary evaporation. The residue was solubilized in 1:1 EtOAc/n-hexane (0.1% 
AcOH) and purified by flash column chromatography using 1:1 EtOAc/n-hexane 
(0.1% AcOH) until the product began to elute, at which point 3:1 EtOAc/n-hexane 
(0.1% AcOH) was used as the solvent. IUPAC Name: (S)-5-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-4-oxohexanoic acid. LC-ESI-MS: m/z calculated 
(M+Na+) 390.4, observed 390.1. 
 
Inhibition of In vitro Transpeptidation Reactions. 
Transpeptidation inhibition assays. Reactions for analysis of the 
preliminary inhibitor substrate analog 1 were prepared from 7 day 37 °C heat-
treated batch 3 SrtApneu and incubated for 24 hours at room temperature before 
quenching with N-ethylmaleimide. Reactions were prepared by combining all 
components shown in Table 4 except sortase, which was added to initiate the 
reaction. HPLC analysis was performed using a Dionex Ultimate 3000 HPLC 
system, which allowed for monitoring by UV/Vis analysis of the separations using 
a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (3.0 x 100 mm) with the 
method (Method B): MeCN (0.1% TFA)/H2O (0.1% TFA) mobile phase. Flow rate 
= 0.7 mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN 
(0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 
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min), re-equilibrate to 10% MeCN (7.1-10.0 min). Percent conversion was 
calculated by dividing the area of the product peak by the addition of total 2,4-
DNP containing reactant and product peak areas at 330 nm. 
Table 3. Reaction conditions for sortase mediated ligation inhibition assays. 
Volume of components used are given in µL. Water was added to 50 uL total 
reaction volume unless otherwise noted. 
 
Reaction 1 2 3 4 5 6 7 
Buffer (500 mM Tris, 
pH 7.5, 150 mM NaCl) 
 
5 5 5 5 5 5 5 
SrtApneu (300 µM) 
 
1.7 1.7 1.7 1.7 1.7 1.7 1.7 
L-Alanine amide HCl 
(100 mM) 
 
5 5 5 5 5 5 0 
Abz-LPATA-GK(Dnp) 
(3.7 mM) 
 
1.4 1.4 1.4 1.4 1.4 1.4 1.4 
Ac-
K(Dnp)LPAG(keto)GAA 
(1.0 mM) 
0 0.5 2.5 5 10 25 0 
 
 
Attempted detection of Sulfenic Acid Modification 
Sulfenic acid labeling reactions. Batch 3 SrtApneu in HEPES buffer (20 mM 
HEPES, 150 mM NaCl) was diluted to 50 µM before NO2-alkyne was added to 
500 µM. For the positive control reaction with H2O2, SrtApneu in HEPES buffer was 
diluted to 10 µM and H2O2 was added to 15 µM before NO2-alkyne was added to 
100 µM. After mixing the solutions, they were allowed to stand for 24 hours at 
room temperature before analysis by LC-MS Dionex Ultimate 3000 HPLC system 
(Thermo Scientific) connected to an expression L compact mass spectrometer 
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(Advion, Inc.) using a Phenomenex Kinetex 2.6 µm, 100 Å C4 column (2.0 x 100 
mm) with the method (Method A): MeCN (0.1% Formic acid)/95% H2O, 5% 
MeCN (0.1% Formic acid) mobile phase. Flow rate = 0.3 mL/min. Gradient = 
10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN (0.5-6.0 min), hold 90% 
MeCN (6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), re-equilibrate to 
10% MeCN (7.1-10.0 min). Data analysis was done in Advion Data Express 
software version 3.0. Mass spectrum deconvolution was achieved through a max 
entropy goodness of fit algorithm to determine uncharged masses of samples 
 
Table 4. Stock solutions and reaction concentrations of the components used in 
sulfenic acid labeling reactions for SrtApneu. All unlabeled values are in µL. * 
denotes the use of a 10 mM stock of NO2-alkyne probe, prepared from 10:1 
dilution of the 50 mM stock with HEPES buffer. 
 
                     Reaction   
  
Stock Solution Reaction 
Concentration 
 1 2 3 
HEPES Buffer (1x) 1x 66 66 92.6 
Batch 3 SrtApneu  
(150 µM) 
 
50 or 10 µM 33 33 6.7 
NO2-alkyne  
(50 or 10 mM) 
 
500 µM 0.5 - 1* 
H2O2 (2.0 mM) 15 um - - 0.75 
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6. Appendix I: NMR Spectra of Synthesized Compounds 	  
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